Hansoh Pharmaceutical (03692.HK): Recombinant Humanized Anti-B7-H3 Monoclonal Antibody for Injection (HS-20093) for the Treatment of Osteosarcoma Included in the Priority Review and Approval Process of the National Medical Products Administration

Zhito Finance APP News, Hansoh Pharmaceutical (03692.HK) announced that on September 14, 2026, based on the positive results of the pivotal Phase III trial ARTEMIS-011 of HS-20093 for injection (recombinant anti-B7-H3 antibody-drug conjugate) (the product), the indication of the product for the treatment of osteosarcoma patients aged >=12 years who have failed at least two prior lines of therapy has been included in the priority review and approval procedure of China's National Medical Products Administration (NMPA).